Patent assignee · DE · COMPANY

BIONTECH SE

🏢 View company profile →
64Patents
64Active
64Granted
59Portfolio score

Filing activity: Jan 29, 2014 → May 10, 2024

Most-cited patents

PatentTitleAreaCited byStatus
US11222711B2 Predicting immunogenicity of T cell epitopes Chemistry; Metallurgy 9 Active
US11547673B1 Coronavirus vaccine Emerging Cross-Sectional Technologies 8 Active
US11091557B2 Methods of producing multispecific antibodies against CD40 and CD137 Chemistry; Metallurgy 6 Active
US11084882B2 Multispecific antibodies against CD40 and CD137 Chemistry; Metallurgy 4 Active
US11779659B2 RNA constructs and uses thereof Emerging Cross-Sectional Technologies 4 Active
US11248264B2 Individualized vaccines for cancer Emerging Cross-Sectional Technologies 2 Active
US11440966B2 Multispecific antibodies against CD40 and CD137 Chemistry; Metallurgy 2 Active
US11878055B1 Coronavirus vaccine Chemistry; Metallurgy 2 Active
US11046745B2 Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof Physics 2 Active
US11267813B2 Substituted imidazoquinolines Emerging Cross-Sectional Technologies 1 Active
US11951185B2 RNA constructs and uses thereof Emerging Cross-Sectional Technologies 1 Active
US11925694B2 Coronavirus vaccine Emerging Cross-Sectional Technologies 1 Active
US11395799B2 Preparation and storage of liposomal RNA formulations suitable for therapy Performing Operations; Transporting 1 Active
US11628209B2 Tumor antigens for determining cancer therapy Physics 1 Active
US11559587B2 RNA formulation for immunotherapy Emerging Cross-Sectional Technologies 1 Active
US10858415B2 Peptide mimotopes of claudin 18.2 and uses thereof Physics 0 Active
US12077596B2 Multispecific antibodies against CD40 and CD137 Chemistry; Metallurgy 0 Active
US11298426B2 Recombinant vaccines and use thereof Chemistry; Metallurgy 0 Active
US12410258B2 Antibodies capable of binding to OX40, variants thereof and uses thereof Chemistry; Metallurgy 0 Active
US11673939B2 Compositions and methods for diagnosis and treatment of cancer Human Necessities 0 Active
US12263215B2 Cytotoxic immunostimulating particles and uses thereof Human Necessities 0 Active
US11814411B2 Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137) Chemistry; Metallurgy 0 Active
US12338448B2 Trans-replicating RNA Chemistry; Metallurgy 0 Active
US11932693B2 Monoclonal antibodies directed against programmed death-1 protein and their use in medicine Chemistry; Metallurgy 0 Active
US11987569B2 Substituted imidazoquinolines as agonists of TLR7 Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.